Product Name | Thrombin Receptor Activator for Peptide 6 (TRAP - 6)SFLLRN |
Size | 1 mg |
Catalog # | AS-24190 |
US$ | $19 |
Purity | % Peak Area By HPLC ≥ 95% |
This peptide forms the N-terminal sequence left after thrombin cleavage of the receptor"s amino-terminal exodomain thereby activating the thrombin receptor PAR1. This sequence then acts as a tethered peptide ligand. Free SFLLRN activates PAR1 independent of receptor cleavage and has been used to probe PAR1 function in various cells and tissues. This peptide is also known to be capable of activating PAR2. | |
Detailed Information | DatasheetMaterial Safety Data Sheets (MSDS) |
Storage | -20°C |
References | 1, Hammes, SR and Coughlin, SR. Biochem, 38:2486-2493 (1999). 2, Scarborough, RM. et al. J. Biol. Chem. 267, 13146 (1992). 3, Ahmad, S. and PN. Walsh, Biochem. 44, 13858 (2005). 4, Buergler, M. et al. J. Thromb. Thrombolysis 19, 115 (2005). |
Molecular Weight | 748.9 |
SFLLRN | |
Sequence(Three-Letter Code) | H - Ser - Phe - Leu - Leu - Arg - Asn - OH |
Product Citations | Birukova, A. et al. (2010). Lung endothelial barrier protection by iloprost in the 2-hit models of ventilator-induced lung injury (VILI) involves inhibition of Rho signaling . Transl Res 155, 44. doi:10.1016/j.trsl.2009.09.002.Jenkins, R. et al. (2006). Ligation of protease-activated receptor 1 enhances αv β6 integrindependent TGF-β activation and promotes acute lung injury. J. Clin. Invest 116, 1606. doi:10.1172/JCI27183.Ludeman, M. et al. (2005). PAR1 Cleavage and signaling in response to activated protein C and thrombin. J Biol Chem 280, 13122. doi:10.1074/jbc.M410381200Birukova, AA. et al. (2004). Novel role of microtubules in thrombin-induced endothelial barrier dysfunction. FASEB J 18, 1879. doi: 10.1096/fj.04-2328comKawkitinarong, K. et al. (2004). Differential Regulation of human lung epithelial and endothelial barrier function by thrombin. Am. J. Respir. Cell. Mol. Biol 31(5), 517. doi:10.1165/rcmb.2003-0432OCLudeman, MJ. et al. (2004). Regulated shedding of PAR1 N-terminal exodomain from endothelial cells. J. Biol. Chem 279, 18592. doi: 10.1074/jbc.M310836200 |
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
mye-mail:pjlitao@tom.com
碳14试剂检测方法
(1) 静坐25分钟后,受试者直接向集气瓶内呼气,患者呼气后集气瓶中的液体由粉红色变成无色为止,或者患者持续呼气时间已经达到3分钟后即可停止呼气。
(2) 向集气瓶中加入4.5ml稀释闪烁液后,加盖旋紧,置于液闪仪中进行检测。
(3) 检查过程中患者应当保持安静,剧烈运动后血中的酸碱度变化可能影响同位素标记CO2的呼出,另外在患者呼气时应当嘱咐患者注意不要将集气瓶中的液体误吸入口腔。
安全性
碳14尿素呼气试验应用于临床十几年,未见到明显的不良反应的报道。专业性评估报告证实碳14呼气试验对患者和操作人员的辐射危险可忽略不计,临床上可以安全使用。
有几个问题想问问大家:
1.我看到相当多文献中,结束反应用的是抽滤,由于条件的限制,我们这里没有该装置,所以就取了少数文献中的方法,用12000G离心10min结束反应,然后沉淀TRIS-HCL洗涤3次。测量时在沉淀所在的EP管中加入闪烁液(该闪烁液的配方适用于样品含水量较少的情况),每管1ML。请问大家,这样结束反应行吗?沉淀是否应该烘干?
2.我用的液闪仪计数不是很稳定,如果进行校正,尤其是读数比较小的时候(如只有数百),以减少误差?
3.加入闪烁液后,是否应该避光放置一段时间后再测量?
谢谢!
mye-mail:pjlitao@tom.com
十分感谢!!!
有几个问题想问问大家:
1.我看到相当多文献中,结束反应用的是抽滤,由于条件的限制,我们这里没有该装置,所以就取了少数文献中的方法,用12000G离心10min结束反应,然后沉淀TRIS-HCL洗涤3次。测量时在沉淀所在的EP管中加入闪烁液(该闪烁液的配方适用于样品含水量较少的情况),每管1ML。请问大家,这样结束反应行吗?沉淀是否应该烘干?
2.我用的液闪仪计数不是很稳定,如果进行校正,尤其是读数比较小的时候(如只有数百),以减少误差?
3.加入闪烁液后,是否应该避光放置一段时间后再测量?
谢谢!